PATENT CLAIM ANALYSIS

Application Number: 15995586
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "722000"]

Abstract:
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, R a , R b , R 1 , R 2  and R 3  are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Claim (Index 13):
The method of  claim 1 , further comprising administering to the subject at least one therapeutic agent selected from the group consisting of:\n (i) an antidepressant selected from amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, reboxetine, robaizotan, sertraline, sibutramine, tianeptine, thionisoxetine, tranylcypromaine, trazodone, trimipramine, venlafaxine, vortioxetine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (ii) an antipsychotic selected from amisulpride, aripiprazole, asenapine, benzisoxidil, bifeprunox, brexpiprazole, carbamazepine, cariprazine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, lurasidone, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutlypiperidine, pimnozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, suproclone, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, zicronapine, ziprasidone, or equivalents, pharmaceutically active isomer(s), and metabolite(s) thereof; (iii) an anxiolytic selected from alnespirone, azapirones, benzodiazepines, barbiturates, adinazolam, alprazolam, balezepam, bentazepam, bromazepam, brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide, cyprazepam, diazepam, diphenhydramine, estazolam, fenobam, flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam, meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam, reclazepam, tracazolate, trepipam, temazepam, triazolam, uldazepam, zolazepam, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (iv) an anticonvulsant selected from carbamazepine, valproate, lamotrigine, levetiracetam, gabapentin, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (v) an Alzheimer's disease therapy selected from donepezil, galantamine, memantine, rivastigmine, tacrine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (vi) a Parkinson's disease therapy selected from L-dopa, ropinirole, pramipexole, monoamine oxidase type B (MAO-B) inhibitors such as deprenyl, selegiline and rasagiline, catechol-0-methyl transferase (COMT) inhibitors, adenosine A-2 inhibitors, dopamine re-uptake inhibitors, NMDA antagonists, nicotine agonists, and dopamine agonists, inhibitors of neuronal nitric oxide synthase, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof, (vii) a migraine therapy selected from almotriptan, amantadine, botulinum toxin A, bromocriptine, butalbital, cabergoline, dichloralphenazone, dihydroergotamine, eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole, sumatriptan, topiramate, zolmitriptan, zomitriptan, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (viii) a stroke therapy selected abciximab, activase, citicoline, desmoteplase, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (ix) a urinary incontinence therapy selected from darafenacin, duloxetine, falvoxate, mirabegron, oxybutynin, propiverine, robalzotan, solifenacin, tolterodine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (x) a neuropathic pain therapies selected from capsaicin, gabapentin, lidoderm, and pregabalin, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.35714
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14625812', '15120048', '15029356', '15320887', '15120002']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8574822238505014
- 35 USC 102 Novelty (BERT): 0.6448995305861344
- Combined Prediction Score: 0.8362239545240648
- Mean Citation Score: 675.908338
- Max Citation Score: 867.8966
- Similarity Product: 577.319640949154

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test